<< Read Full Article
<< Read Full Article
Dendreon Runs to Daylight
The Food and Drug Administration will approve Dendreon's(DNDN Quote) Provenge prostate cancer vaccine on or around its May 15 deadline.
I don't normally start a column with such a declarative opinion, but it seems right in this case. Thursday's positive recommendation from the FDA's advisory panel was a big win for Dendreon.
I stayed neutral on Provenge going into the panel, but the discussion and vote -- despite some strangeness and controversy -- moves me into the pro-Dendreon camp. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,464.40 | 1,110.63 | 2,176.05 | 32.79 |
Oil *
77.05
|
|
UP
30.69
|
UP
4.98
|
UP
6.87
|
DOWN
0.38
|
10 Yr
3.28%
SPDR Gold
116.62
|
|
+0.29%
|
+0.45%
|
+0.32%
|
-1.15%
|
Data delayed 20 minutes |
Connect with TheStreet